Want to see CRVO full AI Analyst Report?
Top Page
CervoMed
(NASDAQ:CRVO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.50
▼(-12.06% Downside)
Action:Reiterated
Date:07/10/26
The score is held back primarily by weak financial performance (minimal and declining revenue, large ongoing losses, and substantial cash burn). Offsetting factors include a debt-free balance sheet and a set of positive corporate developments (trial progress, strengthened IP, and added funding). Technically, signals are mixed with short-term stabilization but longer-term weakness, and valuation is not supportive due to negative earnings and no dividend.
Positive Factors
Clinical trial progress
Completing Phase 2a enrollment and securing biomarker presentation represents durable de-risking of the lead program: fixed trial execution reduces operational uncertainty, enables upcoming objective readouts that can unlock partnerships or registrational planning, and diversifies pipeline evidence beyond DLB.
Negative Factors
Minimal and declining revenue
Persistently minimal and falling revenue underscores that CervoMed remains pre-commercial with no recurring product sales. This diminishes internal funding ability, increases dependency on external capital, and means long-term value hinges entirely on clinical and regulatory outcomes rather than ongoing cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical trial progress
Completing Phase 2a enrollment and securing biomarker presentation represents durable de-risking of the lead program: fixed trial execution reduces operational uncertainty, enables upcoming objective readouts that can unlock partnerships or registrational planning, and diversifies pipeline evidence beyond DLB.
Read all positive factors
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.29M
Dividend YieldN/A
Average Volume (3M)112.80K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue Growth-77.56%
EPS Growth-50.38%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)-3.27
Shares Outstanding13,526,233
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue84.74
Enterprise Value/Gross Profit84.74
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$20.40Price Target Upside412.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.7
Revenue Forecast (FY)$228.57K
CervoMed Business Overview & Revenue Model
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that cro...
How the Company Makes Money
As a clinical-stage biotechnology company, CervoMed does not typically generate recurring product revenue and primarily funds operations through capital-raising activities. Based on publicly available high-level information, specific, itemized rev...
CervoMed Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -30.04M | -26.97M | -16.29M | -2.17M | -5.80M | -15.94M |
| Net Income | -30.04M | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | ||||||
| Total Assets | 15.11M | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 12.92M | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 4.50M | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 10.62M | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | ||||||
| Free Cash Flow | -27.57M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -27.57M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 20.41M | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 4.60M | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
Positive
3.98
Price Trends
3.37
Positive
3.76
Negative
5.62
Negative
Market Momentum
0.07
Negative
52.34
Neutral
59.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Positive. The current price of 3.98 is above the 20-day moving average (MA) of 3.45, above the 50-day MA of 3.37, and below the 200-day MA of 5.62, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 59.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRVO.
CervoMed Risk Analysis
CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CervoMed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $48.29M | -1.09 | -136.08% | ― | -77.56% | -50.38% | |
52 Neutral | $415.95M | -0.97 | -94.90% | ― | -71.26% | -300.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $39.26M | -13.14 | -92.03% | ― | -100.00% | -170.04% | |
44 Neutral | $382.70M | -4.53 | -118.24% | ― | 138.86% | 42.14% | |
41 Neutral | $16.23M | -0.17 | -191.12% | ― | ― | 38.53% |
* Healthcare Sector Average
CRVO
CervoMed
3.57
-3.54
-49.79%
XFOR
X4 Pharmaceuticals
4.41
2.93
197.97%
ABVC
ABVC BioPharma
1.51
-2.00
-56.98%
JSPR
Jasper Therapeutics
0.58
-2.89
-83.31%
PRLD
Prelude Therapeutics
4.81
3.99
485.98%
ESLA
Estrella Immunopharma
0.93
0.05
5.23%
CervoMed Corporate Events
Business Operations and StrategyProduct-Related Announcements
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
Positive
Jul 9, 2026
On July 9, 2026, CervoMed Inc., a clinical-stage biotechnology company developing oral small-molecule therapies for age-related brain disorders, said it has completed enrollment in its Phase 2a trial of lead candidate neflamapimod in nonfluent var...
Business Operations and StrategyPrivate Placements and Financing
CervoMed Raises $10 Million in Direct Offering
Positive
Jun 22, 2026
On June 22, 2026, CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million before fees and expenses. H.C. Wainwright Co. acted as exclusive placement agent, an...
Business Operations and StrategyProduct-Related Announcements
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
Positive
Jun 18, 2026
On June 16, 2026, CervoMed Inc. received a notice of allowance from the U.S. Patent and Trademark Office for a new patent covering the use of its drug candidate neflamapimod to treat dementia with Lewy bodies in patients without substantial Alzhei...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed Posts Updated Investor Presentation and Business Overview
Neutral
Jun 15, 2026
CervoMed Inc. disclosed that summary information about its business, clinical studies, development plans and financial position has been made available in an investor presentation on its website, which representatives may periodically use at confe...
Business Operations and StrategyPrivate Placements and Financing
CervoMed Announces Private Placement to Advance Neurology Pipeline
Positive
Jun 10, 2026
On June 9 and 10, 2026, CervoMed announced a definitive securities purchase agreement for a private placement of 3,360,377 units, each comprising common stock or pre-funded warrants plus Series B and C warrants, expected to raise about $10.5 milli...
Executive/Board ChangesShareholder Meetings
CervoMed Shareholders Back Board, Pay and Incentive Plan
Positive
Jun 9, 2026
At its 2026 Annual Meeting of Stockholders, held on June 8, 2026, CervoMed Inc. reported that holders of approximately 67.2% of its outstanding common stock were present in person or by proxy, establishing a quorum for conducting business. Stockho...
Business Operations and StrategyFinancial Disclosures
CervoMed Highlights Q1 Results and Neflamapimod Progress
Neutral
May 18, 2026
CervoMed reported first-quarter 2026 results on May 18, 2026, highlighting continued progress with its lead candidate neflamapimod across multiple neurodegenerative indications. The company completed Phase 3 trial design for dementia with Lewy bod...
Business Operations and Strategy
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
Positive
Apr 22, 2026
On April 22, 2026, CervoMed reported Phase 2b RewinD-LB trial data presented at the American Academy of Neurology meeting showing that neflamapimod increased basal forebrain volume and enhanced functional connectivity in patients with dementia wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.